PCSK9 and familial hyperaldosteronism: Multiple clinical trials supporting PCSK9 use have been established in patients with FH and include FOURIER (with evolocumab) and ODYSSEY OUTCOMES (with alirocumab): they have shown that PCSK9 inhibitors may decrease LDL-C (up to 60%) and major adverse cardiovascular event rates in high-risk patients considerably [12].